{"name":"Senju Pharmaceutical Co., Ltd.","slug":"senju-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"1996-01-01","label":"Alphagan first approved","drug":"Alphagan","drugSlug":"brimonidine","type":"approval","sentiment":"positive"},{"date":"1996-01-01","label":"Alphagan first approved","drug":"Alphagan","drugSlug":"brimonidine-tartrate","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2029-07-27","label":"Alphagan patent expiry (Method of Use)","drug":"Alphagan","drugSlug":"brimonidine-tartrate","type":"patent_expiry","sentiment":"negative"},{"date":"2031-03-25","label":"Alphagan patent expiry (Formulation)","drug":"Alphagan","drugSlug":"brimonidine-tartrate","type":"patent_expiry","sentiment":"negative"},{"date":"2031-03-25","label":"Alphagan patent expiry (Formulation)","drug":"Alphagan","drugSlug":"brimonidine-tartrate","type":"patent_expiry","sentiment":"negative"},{"date":"2031-03-25","label":"Alphagan patent expiry (Method of Use)","drug":"Alphagan","drugSlug":"brimonidine-tartrate","type":"patent_expiry","sentiment":"negative"},{"date":"2031-03-25","label":"Alphagan patent expiry (Method of Use)","drug":"Alphagan","drugSlug":"brimonidine-tartrate","type":"patent_expiry","sentiment":"negative"},{"date":"2031-06-13","label":"Alphagan patent expiry (Formulation)","drug":"Alphagan","drugSlug":"brimonidine-tartrate","type":"patent_expiry","sentiment":"negative"},{"date":"2031-06-13","label":"Alphagan patent expiry (Formulation)","drug":"Alphagan","drugSlug":"brimonidine-tartrate","type":"patent_expiry","sentiment":"negative"},{"date":"2031-06-13","label":"Alphagan patent expiry (Formulation)","drug":"Alphagan","drugSlug":"brimonidine-tartrate","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Alphagan","genericName":"BRIMONIDINE","slug":"brimonidine","indication":"Ocular hypertension","status":"marketed"},{"name":"Alphagan","genericName":"BRIMONIDINE TARTRATE","slug":"brimonidine-tartrate","indication":"Ocular hypertension","status":"marketed"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"SJP-0035 0.001%","genericName":"SJP-0035 0.001%","slug":"sjp-0035-0-001","indication":"Dry eye disease","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"SJP-0132","genericName":"SJP-0132","slug":"sjp-0132","indication":"Type 2 diabetes","status":"phase_3"}]}],"pipeline":[{"name":"Alphagan","genericName":"BRIMONIDINE","slug":"brimonidine","phase":"marketed","mechanism":"Alpha-2C adrenergic receptor","indications":["Ocular hypertension","Open-angle glaucoma","Rosacea"],"catalyst":""},{"name":"Alphagan","genericName":"BRIMONIDINE TARTRATE","slug":"brimonidine-tartrate","phase":"marketed","mechanism":"Alpha-2C adrenergic receptor","indications":["Ocular hypertension","Open-angle glaucoma","Rosacea"],"catalyst":""},{"name":"SJP-0035 0.001%","genericName":"SJP-0035 0.001%","slug":"sjp-0035-0-001","phase":"phase_3","mechanism":"SJP-0035 is a topical ophthalmic solution used to treat dry eye disease.","indications":["Dry eye disease"],"catalyst":""},{"name":"SJP-0132","genericName":"SJP-0132","slug":"sjp-0132","phase":"phase_3","mechanism":"SJP-0132 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPdmNLcHJIN3I2aFlfN3BRbHVzYUpiY0E4amhOLU1neWpjaXJvSVBtN3ZHVlFuNDNMdTVMaFBjU2Zuc1BkVmppaXZjM0l4c1lxTllZSTAtZEgxT0g0UGJ4U2UtT2xJQVlFUHk3anl4Y016dzJDWmV0WGNlMThoNXJ6SEhHWWsyQUhtU1pyTXM2RVVJeWVseVlIQUln?oc=5","date":"2026-04-07","type":"pipeline","source":"The Pharma Letter","summary":"Senju and Mochida announce Avarept launch in Japan - The Pharma Letter","headline":"Senju and Mochida announce Avarept launch in Japan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxOeFRzb2ctNFlwaG5abm1HQktueW1wXzd4cEJTblpvd0tOMjFnSlVaNXBoNGpiZy1KbnJJcGdXQkN5SUFjanRMUUo4cHllbUhjSm93TjE2aml5VHo2SFlpT2RZMDVKTW5IcG8tNlh5a1FnXzFqZUItV0w0VVpHZTl5cXFudHdMNmNrZ1lOWEplUThmWGphSjQtUllvbGVLcWhCQUNaZWxpNXU5NC1reTZJSnVUY2swOWFycUlTY3NOZzhRbVNPR19maTZjWVY1Q1JpRWJJMDQ1WDZFMXhqcnNoQ2R1UjdORUhiYzYwN01wNkFhcFNEOXRUUk90VmtuRktuUWNhYnM2dThjTEZwQ3VGSk1vSTBybnpITkZOZjN2TnA?oc=5","date":"2026-03-25","type":"trial","source":"TMX Newsfile","summary":"Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials - TMX Newsfile","headline":"Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxOQU1UMVRBUlRIaE15U0JBd0wtR0gyVEt0N3pOeXZhWnZCdVAyX2tYNXJfTnV3M015b3ZJQ3N4WnlvdF85Y3pjRjU5R1ctMUdyMEktYVRCSjdrejhzaXk4UThiN1JCYVFBVzhzWnZPYTZkNEJReUlOQjU0VHZQc3l1VDN3SDlwT096NlY3N1d0blJEblRmUXpQUTF2SVZrbEdGMXhQbkF3aTBBTWpJMkk2bXplX2YyM3dXcW9LanVnZTZYNzdWNWhsZ3lQUkZOZGlUeUUyVHNNdWRmWVE?oc=5","date":"2025-06-05","type":"deal","source":"Ophthalmology Times","summary":"Kiora Pharmaceuticals and Senju Pharmaceutical partner on KIO-301 for retinal disease treatment in Asia - Ophthalmology Times","headline":"Kiora Pharmaceuticals and Senju Pharmaceutical partner on KIO-301 for retinal disease treatment in Asia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPQ1FYWmZjZDI2NUdtOVo4ZXZwZ2U0VHcyeFVhanlQVzIzdWFyOGF2SnZXTTE5WDYwU1FNVFhVRXU1d0c4YVF5RlZieTNpVUR6OFdROXk5LTVpY3RDQU9VVHU3Wl9TeEdOQk9lNXV3YzdhOEkzWlNtX0d3M1RxWkV6X2I2TlNvQkZ0aG9iZWhocjRDWWtwS21vVjJWSFI?oc=5","date":"2025-06-03","type":"deal","source":"Yahoo Finance","summary":"Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in Asia - Yahoo Finance","headline":"Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in Asia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9qaGpGRHFuVTU1akxSdDNpMktvamNLdUhTa3ZzSmJpbDVkZzdhSl9LWjh3RTF4SWU2eXJsazJqTVJWMWhFTkFQampmVm8tVU9mNlBn?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"KPRX Stock Price, News & Analysis - Stock Titan","headline":"KPRX Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxNUTlueFcxMloxdHhmMklNRmVicU9oc1hZMkY1dElEeUNUeWJTdmV2YzJycktUNG1STmthZ1FOLXBweTM4WTZCZVF4TXc3VHVXS01rdUhfMXVUZmp4N3VBQUR5RkI2M2Q3b1pGaGNzeG5OZDF1YmdHWFZVQkkyMS1HTV9zMG96WEluMk12MU5XaEVWWHhhZXpmZ19Fd2pSelNuN0FoVXozMERsVHd0YnJVdlYyb1d1LTNJU1NQdWItM3hxZ3RlZ01mcw?oc=5","date":"2025-01-28","type":"pipeline","source":"PR Newswire","summary":"Dry Eye Disease Market to Observe Stupendous Growth by 2034 | DelveInsight - PR Newswire","headline":"Dry Eye Disease Market to Observe Stupendous Growth by 2034 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNTXc3RE05VUc5Y09aN2VDMXlNd215LXJSQ19sbENLV3ZBY0RCMFlPdlFjMXNTZFcyZ1cxd1FJT1hCbjdiWEVYc1BVOE1Td0VzcWl2cjl2M0R4eTRyMXJJdW5mSGEyS0J3QWNZRGRIbkRWdE5BTkJxSkRqc2FZbkRfWlFxNTNfcXVaX18xOVJRSjlfeUJQZjRneXUwbGozMUY4bUh1dGVPRDlraWQ4TDU3TjAxTnp4dFFp?oc=5","date":"2024-07-24","type":"deal","source":"Ophthalmology Times","summary":"Eyenovia, Inc. and Senju Pharmaceutical Co., Ltd. sign new collaboration agreement - Ophthalmology Times","headline":"Eyenovia, Inc. and Senju Pharmaceutical Co., Ltd. sign new collaboration agreement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9nYnh5VnFkZ0hubm9TeUw0ck5JRGZBZm1WcnF1Y3VBUTlGc3NJek9NTmNrYVNsN2MxenBKZlptYVFiNmRRaFFZVGFGMWZUNUY4LTViQm5aaURMR0xfU0lF?oc=5","date":"2024-05-22","type":"pipeline","source":"Nature","summary":"One-year outcomes and safety assessment of faricimab in treatment-naïve patients with neovascular age-related macular degeneration in Japan - Nature","headline":"One-year outcomes and safety assessment of faricimab in treatment-naïve patients with neovascular age-related macular de","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPNlYtcU0wb2FCM3RvTjFfQXJNczRmTlMycFRERXNDYzlnOGZTeUU0aFpuTWVRZDI3Z3JSc0I0LVEtNkdTU3ptWjJTRllWZ2NKTG05S1o2M2ptTkZvUUNZYXlFSk45dHhXU2U2aTMwTDVWS28yNTZkVVYyenpRSWtGd1ZGRE1oYmVfd1ROSjRKVjZyMVZBMmR4LVhXaXpNTE12TVRIWlRJV1JfUnVHckF4RWF0a0dvUzA?oc=5","date":"2023-03-09","type":"pipeline","source":"Pharmaceutical Technology","summary":"Who are the leading innovators in cell therapy for ocular disorders for the pharmaceutical industry? - Pharmaceutical Technology","headline":"Who are the leading innovators in cell therapy for ocular disorders for the pharmaceutical industry?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTE5DcENobzRpQjRHOWs5a1BSZ3pmOWpoRXY4QlNGdkl1dWhhUHhmNW9xajBNX0lkZkYzczFNWngyV1RZSlQ2Q0FZck1UYk5nRkNiQ0JkamZ1VlNDbjQ?oc=5","date":"2022-09-28","type":"pipeline","source":"EurekAlert!","summary":"DryEyeRhythm: A reliable, valid, and non-invasive app to assess dry eye disease - EurekAlert!","headline":"DryEyeRhythm: A reliable, valid, and non-invasive app to assess dry eye disease - EurekAlert!","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTFBJeWVUNjBHUUNXZi1OYUl3WVZfdzdYWXpia19nNWkzZVJFUWg5S2cxM2gyM3YtTEtQVldLTW5vVVdZd0pmcDJUc01ybTdTZHVnMjNueUNmSFlQdkVPSzNqWnNxRmpYdEM5?oc=5","date":"2022-05-19","type":"pipeline","source":"Wiley Online Library","summary":"Presumed congenital nictitating membrane dysplasia in a Japanese white rabbit - Wiley Online Library","headline":"Presumed congenital nictitating membrane dysplasia in a Japanese white rabbit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE5NMkQtZUdWd1BfbUlrX0NPZW8tOVI4dDFFUl9mMnVSMFhLUXJ2M0dUeUlzV1RHT0VKSDRzMkFyQUhrMXpqSjJtcGZ2amhNWVJrSU1nOUxIRWh3WWZ4NDIzaGN0bU5RbTdhMzluNGJpRTY4dXNLdDBR?oc=5","date":"2015-01-26","type":"pipeline","source":"JD Supra","summary":"Court Report - January 2015 #2 | McDonnell Boehnen Hulbert & Berghoff LLP - JD Supra","headline":"Court Report - January 2015 #2 | McDonnell Boehnen Hulbert & Berghoff LLP","sentiment":"neutral"}],"patents":[{"drugName":"Alphagan","drugSlug":"brimonidine-tartrate","patentNumber":"11833245","type":"Method of Use","expiryDate":"2029-07-27","territory":"US","genericFilings":[]},{"drugName":"Alphagan","drugSlug":"brimonidine-tartrate","patentNumber":"8513247","type":"Formulation","expiryDate":"2031-03-25","territory":"US","genericFilings":[]},{"drugName":"Alphagan","drugSlug":"brimonidine-tartrate","patentNumber":"8513249","type":"Formulation","expiryDate":"2031-03-25","territory":"US","genericFilings":[]},{"drugName":"Alphagan","drugSlug":"brimonidine-tartrate","patentNumber":"9861631","type":"Method of Use","expiryDate":"2031-03-25","territory":"US","genericFilings":[]},{"drugName":"Alphagan","drugSlug":"brimonidine-tartrate","patentNumber":"9861632","type":"Method of Use","expiryDate":"2031-03-25","territory":"US","genericFilings":[]},{"drugName":"Alphagan","drugSlug":"brimonidine-tartrate","patentNumber":"8053427","type":"Formulation","expiryDate":"2031-06-13","territory":"US","genericFilings":[]},{"drugName":"Alphagan","drugSlug":"brimonidine-tartrate","patentNumber":"8163725","type":"Formulation","expiryDate":"2031-06-13","territory":"US","genericFilings":[]},{"drugName":"Alphagan","drugSlug":"brimonidine-tartrate","patentNumber":"10201517","type":"Formulation","expiryDate":"2031-06-13","territory":"US","genericFilings":[]}],"drugCount":4,"phaseCounts":{"marketed":2,"phase_3":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}